The South African Tuberculosis Vaccine Initiative (SATVI) has announced the roll out of a Phase 2a trial of the ID 93+GLA-SE tuberculosis (TB) vaccine candidate, which is being conducted in partnership with the Infectious Disease Research Institute (IDRI) and the Welcome Trust.
The South African Tuberculosis Vaccine Initiative has published a research paper titled "A randomized clinical trial in adults and newborns in South Africa to compare the safety and immunogenicity of bacille Calmette-Guérin (BCG) vaccine administration via a disposable-syringe jet injector to conventional technique with needle and syringe.
We are seeking a motivated and enthusiastic Project Manager and invite applications from suitably qualified candidates to this position as Project Manager.
Closing Date: 11 October 2015
The South African Tuberculosis Vaccine Initiative (SATVI) announces the departure of Dr Zameer Brey, who left SATVI at the end of August 2015 to join the Bill & Melinda Gates Foundation.